Duvyzat (Givinostat Hydrochloride) Patent Expiration, LOE Window & CMS Spending
Duvyzat (Givinostat Hydrochloride) by Italfarmaco Spa: FDA Orange Book core substance LOE 2040-05-03, 0 AB generics, $25.2M 2024 CMS Part D & Medicaid spend, and $37,000 CA SB 17 specialty launch WAC.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Italfarmaco Spa |
| FDA Application & Pathway | N217865 (NDA) |
| Exclusivity / Cliff Horizon | Long-Dated Protection (2036+) |
| Core Active-Ingredient LOE Date | 2040-05-03 |
| Last Listed Patent or Exclusivity Date | 2040-05-03 |
| Orange Book Patents (*PED Extensions) | 5 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $25.2M |
| 2024 Medicare Part D Spend | $2.0M |
| 2024 Medicaid Spend | $23.2M |
| Reported Wholesale Price Change (CA SB 17) | Specialty launch notice ($37,000 intro WAC) |